Heparin Market Size & Share to Record New Values for the Forecast Period 2020-2030
Market Overview
Heparin, commonly known as unfractionated heparin (UFH), is a naturally occurring glycosaminoglycan. It is used in medicine as an anticoagulant (blood thinner). It is very beneficial in the treatment of heart attacks and angina pectoris. It's injected either into a vein or under the skin. Acute coronary syndrome, deep vein thrombosis, pulmonary embolism, and atrial fibrillation, as well as cardiopulmonary bypass and hemofiltration during heart surgery, are all treated with it. It can also be used to provide major orthopedic surgeries like hip and knee replacements. The COVID-19 pandemic has caused chaos on health-care workflows all around the world. A huge number of individuals are suffering from coronavirus, which is associated to respiratory disorders, during the COVID-19 pandemic. As a result, the demand for heparin has risen, as it aids in the management of pulmonary inflation and the thinning of the blood of people at risk of a blood clot.
Heparin Market: Key Players
Baxter International Inc.
Company Overview, Business Strategy, Key Product Offerings, Financial Performance, Key Performance Indicators, Risk Analysis, Recent Development, Regional Presence, SWOT Analysis
B. Braun Holding GmbH & Co. KG
Dr. Reddy’s Laboratories Ltd.
Fresenius SE & Co KGaA
Hebei Changshan Biochemical Pharmaceutical Co. Ltd.
Leo Pharma A/S
Pfizer Inc.
Sanofi S.A
Teva Pharmaceuticals
Viatris Inc.
Growth Factor
Rising Incidence of Chronic Disorders to Incite market growth
The rising global prevalence of cardiovascular disorders, such as heart attacks and strokes, will provide market possibilities. According to the American Heart Association's (AHA) Heart Disease and Stroke Statistics, atrial fibrillation affected 5.3 million Americans in 2019. The rising patient demand for heparin might have a significant influence on the market.
Segmentation
By Product
Unfractionated Heparin
Low Molecular Weight Heparin (LMWH)
Ultra-low Molecular Weight Heparin (ULMWH)
By Application
Venous Thromboembolism
Coronary Artery Disease
Atrial Fibrillation
Others
By Distribution Channel
Hospital Pharmacies
Drug Stores & Retail Pharmacies
Online Pharmacies
Heparin market Dynamics
Heparin market Size
Supply & Demand
Current Trends/Issues/Challenges
Competition & Companies Involved in the Market
Value Chain of the Market
Market Drivers and Restraints
Recent News Related to Market
In December 2020, Valeo Pharma Inc. gained approval from Health Canada for its low molecular weight heparin 'Redesca and Redesca HP'.
In May 2020, The University of Manitoba launched a research research to see if heparin, a blood-thinning medicine, can be used to treat COVID-19 patients. The clinical experiment took place in 35 different locations across Canada, the United States, Mexico, and Brazil.
The report sheds light on various aspects and answers pertinent questions on the market. Some of the important ones are:
COVID-19 pre and post business impact analysis
Detailed overview of the parent market
Changing market dynamics in the industry
In-depth market segmentation
What is the Heparin market growth?
Which segment accounted for the largest Heparin market share?
Who are the key players in the Heparin market?
Historical, current and projected market size in terms of volume and value
Recent industry trends and developments
Competitive landscape
Strategies of key players and products offered
Potential and niche segments, geographical regions exhibiting promising growth
A neutral perspective on market performance
Must-have information for market players to sustain and enhance their market footprint
Note: Although care has been taken to maintain the highest levels of accuracy in Fatpos Global’s reports, recent market/vendor-specific changes may take time to reflect in the analysis.
Heparin, commonly known as unfractionated heparin (UFH), is a naturally occurring glycosaminoglycan. It is used in medicine as an anticoagulant (blood thinner). It is very beneficial in the treatment of heart attacks and angina pectoris. It's injected either into a vein or under the skin. Acute coronary syndrome, deep vein thrombosis, pulmonary embolism, and atrial fibrillation, as well as cardiopulmonary bypass and hemofiltration during heart surgery, are all treated with it. It can also be used to provide major orthopedic surgeries like hip and knee replacements. The COVID-19 pandemic has caused chaos on health-care workflows all around the world. A huge number of individuals are suffering from coronavirus, which is associated to respiratory disorders, during the COVID-19 pandemic. As a result, the demand for heparin has risen, as it aids in the management of pulmonary inflation and the thinning of the blood of people at risk of a blood clot.
Heparin Market: Key Players
Baxter International Inc.
Company Overview, Business Strategy, Key Product Offerings, Financial Performance, Key Performance Indicators, Risk Analysis, Recent Development, Regional Presence, SWOT Analysis
B. Braun Holding GmbH & Co. KG
Dr. Reddy’s Laboratories Ltd.
Fresenius SE & Co KGaA
Hebei Changshan Biochemical Pharmaceutical Co. Ltd.
Leo Pharma A/S
Pfizer Inc.
Sanofi S.A
Teva Pharmaceuticals
Viatris Inc.
Growth Factor
Rising Incidence of Chronic Disorders to Incite market growth
The rising global prevalence of cardiovascular disorders, such as heart attacks and strokes, will provide market possibilities. According to the American Heart Association's (AHA) Heart Disease and Stroke Statistics, atrial fibrillation affected 5.3 million Americans in 2019. The rising patient demand for heparin might have a significant influence on the market.
Segmentation
By Product
Unfractionated Heparin
Low Molecular Weight Heparin (LMWH)
Ultra-low Molecular Weight Heparin (ULMWH)
By Application
Venous Thromboembolism
Coronary Artery Disease
Atrial Fibrillation
Others
By Distribution Channel
Hospital Pharmacies
Drug Stores & Retail Pharmacies
Online Pharmacies
Heparin market Dynamics
Heparin market Size
Supply & Demand
Current Trends/Issues/Challenges
Competition & Companies Involved in the Market
Value Chain of the Market
Market Drivers and Restraints
Recent News Related to Market
In December 2020, Valeo Pharma Inc. gained approval from Health Canada for its low molecular weight heparin 'Redesca and Redesca HP'.
In May 2020, The University of Manitoba launched a research research to see if heparin, a blood-thinning medicine, can be used to treat COVID-19 patients. The clinical experiment took place in 35 different locations across Canada, the United States, Mexico, and Brazil.
The report sheds light on various aspects and answers pertinent questions on the market. Some of the important ones are:
COVID-19 pre and post business impact analysis
Detailed overview of the parent market
Changing market dynamics in the industry
In-depth market segmentation
What is the Heparin market growth?
Which segment accounted for the largest Heparin market share?
Who are the key players in the Heparin market?
Historical, current and projected market size in terms of volume and value
Recent industry trends and developments
Competitive landscape
Strategies of key players and products offered
Potential and niche segments, geographical regions exhibiting promising growth
A neutral perspective on market performance
Must-have information for market players to sustain and enhance their market footprint
Note: Although care has been taken to maintain the highest levels of accuracy in Fatpos Global’s reports, recent market/vendor-specific changes may take time to reflect in the analysis.
1. EXECUTIVE SUMMARY
2. GLOBAL HEPARIN MARKET
2.1. Product Overview
2.2. Market Definition
2.3. Segmentation
2.4. Assumptions and Acronyms
3. RESEARCH METHODOLOGY
3.1. Research Objectives
3.2. Primary Research
3.3. Secondary Research
3.4. Forecast Model
3.5. Market Size Estimation
4. AVERAGE PRICING ANALYSIS
5. MACRO-ECONOMIC INDICATORS
6. MARKET DYNAMICS
6.1. Growth Drivers
6.2. Restraints
6.3. Opportunity
6.4. Trends
7. CORRELATION & REGRESSION ANALYSIS
7.1. Correlation Matrix
7.2. Regression Matrix
8. RECENT DEVELOPMENT, POLICIES & REGULATORY LANDSCAPE
9. RISK ANALYSIS
9.1. Demand Risk Analysis
9.2. Supply Risk Analysis
10. GLOBAL HEPARIN MARKET ANALYSIS
10.1. Porters Five Forces
10.1.1. Threat of New Entrants
10.1.2. Bargaining Power of Suppliers
10.1.3. Threat of Substitutes
10.1.4. Rivalry
10.2. PEST Analysis
10.2.1. Political
10.2.2. Economic
10.2.3. Social
10.2.4. Technological
11. GLOBAL HEPARIN MARKET
11.1. Market Size & forecast, 2020A-2030F
11.1.1. By Value (USD Million) 2020-2030F; Y-o-Y Growth (%) 2021-2030F
11.1.2. By Volume (Million Units) 2020-2030F; Y-o-Y Growth (%) 2021-2030F
12. GLOBAL HEPARIN MARKET: MARKET SEGMENTATION
12.1. By Regions
12.1.1. North America:(U.S., Mexico and Canada), By Value (USD Million) 2020-2030F; Y-o-Y Growth (%) 2021-2030F
12.1.2. Europe: (Germany, UK, France, Italy, Spain, Russia and Rest of Europe), By Value (USD Million) 2020-2030F; Y-o-Y Growth (%) 2021-2030F
12.1.3. Asia-Pacific: (China, India, Japan, Australia and Rest of Asia Pacific), By Value (USD Million) 2020-2030F; Y-o-Y Growth (%) 2021-2030F
12.1.4. LAMEA: (Brazil, Saudi Arabia, South Africa, Rest of LAMEA), By Value (USD Million) 2020-2030F; Y-o-Y Growth (%) 2021-2030F
12.2. By Product: Market Share (2020-2030F)
12.2.1. Unfractionated Heparin, By Value (USD Million) 2020-2030F; Y-o-Y Growth (%) 2021-2030F
12.2.2. Low Molecular Weight Heparin (LMWH), By Value (USD Million) 2020-2030F; Y-o-Y Growth (%) 2021-2030F
12.2.3. Ultra-low Molecular Weight Heparin (ULMWH), By Value (USD Million) 2020-2030F; Y-o-Y Growth (%) 2021-2030F
12.3. By Application: Market Share (2020-2030F)
12.3.1. Venous Thromboembolism, By Value (USD Million) 2020-2030F; Y-o-Y Growth (%) 2021-2030F
12.3.2. Coronary Artery Disease, By Value (USD Million) 2020-2030F; Y-o-Y Growth (%) 2021-2030F
12.3.3. Atrial Fibrillation, By Value (USD Million) 2020-2030F; Y-o-Y Growth (%) 2021-2030F
12.3.4. Others, By Value (USD Million) 2020-2030F; Y-o-Y Growth (%) 2021-2030F
12.4. By Distribution channel: Market Share (2020-2030F)
12.4.1. Hospital Pharmacies, By Value (USD Million) 2020-2030F; Y-o-Y Growth (%) 2021-2030F
12.4.2. Drug Stores & Retail Pharmacies, By Value (USD Million) 2020-2030F; Y-o-Y Growth (%) 2021-2030F
12.4.3. Online Pharmacies, By Value (USD Million) 2020-2030F; Y-o-Y Growth (%) 2021-2030F
13. COMPANY PROFILE
13.1. Baxter International Inc.
13.1.1. Company Overview
13.1.2. Company Total Revenue (Financials)
13.1.3. Market Potential
13.1.4. Global Presence
13.1.5. Key Performance Indicators
13.1.6. SWOT Analysis
13.1.7. Product Launch
13.2. B. Braun Holding GmbH & Co. KG
13.3. Dr. Reddy’s Laboratories Ltd.
13.4. Fresenius SE & Co KGaA
13.5. Hebei Changshan Biochemical Pharmaceutical Co. Ltd.
13.6. Leo Pharma A/S
13.7. Pfizer Inc.
13.8. Sanofi S.A
13.9. Viatris Inc.
13.10. Teva Pharmaceuticals
Consultant Recommendation
**The above-given segmentations and companies could be subjected to further modification based on in-depth feasibility studies conducted for the final deliverable.
2. GLOBAL HEPARIN MARKET
2.1. Product Overview
2.2. Market Definition
2.3. Segmentation
2.4. Assumptions and Acronyms
3. RESEARCH METHODOLOGY
3.1. Research Objectives
3.2. Primary Research
3.3. Secondary Research
3.4. Forecast Model
3.5. Market Size Estimation
4. AVERAGE PRICING ANALYSIS
5. MACRO-ECONOMIC INDICATORS
6. MARKET DYNAMICS
6.1. Growth Drivers
6.2. Restraints
6.3. Opportunity
6.4. Trends
7. CORRELATION & REGRESSION ANALYSIS
7.1. Correlation Matrix
7.2. Regression Matrix
8. RECENT DEVELOPMENT, POLICIES & REGULATORY LANDSCAPE
9. RISK ANALYSIS
9.1. Demand Risk Analysis
9.2. Supply Risk Analysis
10. GLOBAL HEPARIN MARKET ANALYSIS
10.1. Porters Five Forces
10.1.1. Threat of New Entrants
10.1.2. Bargaining Power of Suppliers
10.1.3. Threat of Substitutes
10.1.4. Rivalry
10.2. PEST Analysis
10.2.1. Political
10.2.2. Economic
10.2.3. Social
10.2.4. Technological
11. GLOBAL HEPARIN MARKET
11.1. Market Size & forecast, 2020A-2030F
11.1.1. By Value (USD Million) 2020-2030F; Y-o-Y Growth (%) 2021-2030F
11.1.2. By Volume (Million Units) 2020-2030F; Y-o-Y Growth (%) 2021-2030F
12. GLOBAL HEPARIN MARKET: MARKET SEGMENTATION
12.1. By Regions
12.1.1. North America:(U.S., Mexico and Canada), By Value (USD Million) 2020-2030F; Y-o-Y Growth (%) 2021-2030F
12.1.2. Europe: (Germany, UK, France, Italy, Spain, Russia and Rest of Europe), By Value (USD Million) 2020-2030F; Y-o-Y Growth (%) 2021-2030F
12.1.3. Asia-Pacific: (China, India, Japan, Australia and Rest of Asia Pacific), By Value (USD Million) 2020-2030F; Y-o-Y Growth (%) 2021-2030F
12.1.4. LAMEA: (Brazil, Saudi Arabia, South Africa, Rest of LAMEA), By Value (USD Million) 2020-2030F; Y-o-Y Growth (%) 2021-2030F
12.2. By Product: Market Share (2020-2030F)
12.2.1. Unfractionated Heparin, By Value (USD Million) 2020-2030F; Y-o-Y Growth (%) 2021-2030F
12.2.2. Low Molecular Weight Heparin (LMWH), By Value (USD Million) 2020-2030F; Y-o-Y Growth (%) 2021-2030F
12.2.3. Ultra-low Molecular Weight Heparin (ULMWH), By Value (USD Million) 2020-2030F; Y-o-Y Growth (%) 2021-2030F
12.3. By Application: Market Share (2020-2030F)
12.3.1. Venous Thromboembolism, By Value (USD Million) 2020-2030F; Y-o-Y Growth (%) 2021-2030F
12.3.2. Coronary Artery Disease, By Value (USD Million) 2020-2030F; Y-o-Y Growth (%) 2021-2030F
12.3.3. Atrial Fibrillation, By Value (USD Million) 2020-2030F; Y-o-Y Growth (%) 2021-2030F
12.3.4. Others, By Value (USD Million) 2020-2030F; Y-o-Y Growth (%) 2021-2030F
12.4. By Distribution channel: Market Share (2020-2030F)
12.4.1. Hospital Pharmacies, By Value (USD Million) 2020-2030F; Y-o-Y Growth (%) 2021-2030F
12.4.2. Drug Stores & Retail Pharmacies, By Value (USD Million) 2020-2030F; Y-o-Y Growth (%) 2021-2030F
12.4.3. Online Pharmacies, By Value (USD Million) 2020-2030F; Y-o-Y Growth (%) 2021-2030F
13. COMPANY PROFILE
13.1. Baxter International Inc.
13.1.1. Company Overview
13.1.2. Company Total Revenue (Financials)
13.1.3. Market Potential
13.1.4. Global Presence
13.1.5. Key Performance Indicators
13.1.6. SWOT Analysis
13.1.7. Product Launch
13.2. B. Braun Holding GmbH & Co. KG
13.3. Dr. Reddy’s Laboratories Ltd.
13.4. Fresenius SE & Co KGaA
13.5. Hebei Changshan Biochemical Pharmaceutical Co. Ltd.
13.6. Leo Pharma A/S
13.7. Pfizer Inc.
13.8. Sanofi S.A
13.9. Viatris Inc.
13.10. Teva Pharmaceuticals
Consultant Recommendation
**The above-given segmentations and companies could be subjected to further modification based on in-depth feasibility studies conducted for the final deliverable.
